Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. - Wikidata - wikimedia - TriplyDB

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q37282307

about

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Allogeneic stem cell transplantation for multiple myeloma: is there a future?Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Immunologic approaches for the treatment of multiple myeloma.Life after transplant: are we becoming high maintenance in AML?Management of high-risk Myeloma: an evidence-based review of treatment strategies.A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.A Novel Green Synthesis of Thalidomide and Analogs

P2860

Q26782868-0D7AD389-8D23-4C18-8D77-676C76B3864B Q36000415-741E11D4-E7CB-4603-852C-37D44E50FD77 Q36031316-8139F156-8B2C-44E9-961C-C758F72D8C49 Q36963203-B1E52523-4281-47F1-A5CA-D9AB79F10277 Q37012554-44745E4E-7D9C-499D-858F-775111FDFF62 Q38417073-E5012606-3317-4352-9539-822DEAB9DA5B Q38685796-301CC737-CC0E-4ECB-A7EA-C14DD8EB339E Q38688055-B981FA3B-8D56-41A4-A028-3523B427CF4C Q38692244-3A35A37C-9E6F-4278-9CC2-782BDFFDA5D9 Q38801124-A44B4E57-D5F8-474C-8797-2C219B099079 Q38874675-FF494572-3849-43B1-B934-5B6FCA57B0A2 Q39112978-8A2F8E4D-2D13-4590-B9C2-924C2577F55D Q39174731-04F1C25A-7DEA-4E1F-A393-FD271DABAC19 Q39307476-8FB9324A-CBA1-412D-B686-746824AE92F3 Q39933810-1A700AC6-31CF-4B0E-822D-1F3841D160C0 Q41031177-F44D821B-4AD2-4061-AF36-3EB2E412D088 Q41593035-4070553F-1FAF-4B9B-B288-5256A50352CF Q47794767-9E5C11CC-79E6-4788-A8CD-E2E2CD6BE14C Q48094910-4C62DB3A-8032-48CA-8F2E-16EC61FD66A6 Q48193682-F2C2B17E-8F24-49E6-9EBE-4CDCDF8A94E4 Q59145948-29C69E01-902F-4988-8A07-CD709C8F9D13

P2860

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q37282307

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@en

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@nl

type

label

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@en

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@nl

prefLabel

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@en

Lenalidomide maintenance for h ...... opoietic cell transplantation.

@nl

P1433

Q37282307-514373FF-9180-4B10-9B19-761944A6B0BB

P1476

Q37282307-466A80B6-3BE4-46B6-B744-6076ED9AD146

P2093

Q37282307-2342F905-104E-4ACC-BFDE-2ED008FABA27

Q37282307-3A1BA3F8-2204-4B53-A27F-01043BFE3A45

Q37282307-6CCF0785-A492-4D78-9015-0135E70E1CA7

Q37282307-74765B19-1620-4634-991E-211D0B3383B6

Q37282307-87CFEFA7-E5FA-4DB6-B813-F05F60F4BB08

Q37282307-982C4186-ACB9-40C1-8858-6CE335D5E9ED

Q37282307-9C41A312-9FBC-45D5-BAA6-62AE46EADE6F

Q37282307-A244E6DB-07DB-43B6-BF50-039FEE77A597

Q37282307-B545101F-F419-4A78-84E3-D59A6C9432F9

Q37282307-B9F67D2A-08DA-4F63-8B87-D0878D11EB22

P2860

Q37282307-0660855F-4044-4DED-9E22-46057A8E02B6

Q37282307-15BE46B4-19C0-4A4D-B3C7-B19612D09A65

Q37282307-1D797443-7EF7-427A-91F0-353DF91A04DD

Q37282307-1EF69E8D-A1DA-4FA1-AECF-F3FCE448F102

Q37282307-346727D1-5E01-482C-BFBA-402148C0AFE3

Q37282307-3E5F56A7-598D-4F31-9F87-48E2E73CBF36

Q37282307-48C047FE-531F-4A11-B93F-1B93EF50B25C

Q37282307-5DA51454-B6CD-43CD-809B-C398ED800B88

Q37282307-61383389-5358-4DE1-9D15-08725E86833E

Q37282307-8781B26C-E01F-4EAA-B90D-64FA9438B3F2

P304

Q37282307-26F0B11A-C0E3-4247-B50B-5AD81EA32028

P31

Q37282307-27AD0CB8-EF80-4C25-B832-C674F3DA59BB

P356

Q37282307-BC87E2DB-EE73-468F-8E30-542DAC6CE038

P433

Q37282307-0EA7AEB7-B752-4042-9AD8-8BB8FC0E94FB

P478

Q37282307-379CA40B-563F-48F3-B75B-1D28E8C7AA9C

P50

Q37282307-2848697A-7F81-4D20-B32C-E5DC4E76BA9F

P577

Q37282307-2948C213-2A0A-46A7-B7BC-5B0BDAACA0BC

P5875

Q37282307-3CB37CFE-3FB7-401D-A900-5111E562295F

P698

Q37282307-ABB9E4B4-89B0-44BF-94B4-25D160AD2CBD

P932

Q37282307-B1322E9B-BE5E-4BB4-847F-F355CDFD51EF

P356

J.BBMT.2014.04.014

P1433

Biology of Blood and Marrow Transplantation

P1476

Lenalidomide maintenance for h ...... topoietic cell transplantation

@en

P2093

Alexia Adams

http://www.w3.org/2001/XMLSchema#string

Brent Logan

http://www.w3.org/2001/XMLSchema#string

Brian McClune

http://www.w3.org/2001/XMLSchema#string

Daniel Weisdorf

http://www.w3.org/2001/XMLSchema#string

David H Vesole

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Leslie L Popplewell

http://www.w3.org/2001/XMLSchema#string

Marcelo C Pasquini

http://www.w3.org/2001/XMLSchema#string

Marcie Riches

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Lenalidomide after stem-cell transplantation for multiple myeloma

International uniform response criteria for multiple myeloma.

A comparison of allografting with autografting for newly diagnosed myeloma.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Cure of multiple myeloma -- more hype, less reality.

A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

P304

1183-1189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2014.04.014

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Parameswaran Hari

P577

2014-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261919588

http://www.w3.org/2001/XMLSchema#string

P698

24769014

http://www.w3.org/2001/XMLSchema#string

P932

5036168

http://www.w3.org/2001/XMLSchema#string